Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026
Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026
Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026
Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026
Company Deals

Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market

Fineline Cube May 12, 2026
Policy / Regulatory

NMPA Releases 105th Batch of Generic Drug Reference Standards, Adding 37 New Specifications

Fineline Cube May 12, 2026
Company Drug

Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma

Fineline Cube May 12, 2026
Company Drug

Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC

Fineline Cube May 12, 2026
Company Deals

BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia

Fineline Cube Mar 20, 2023

US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...

Company Deals

Gracell Secures Non-Exclusive License for Cell Therapies from Seagen

Fineline Cube Mar 20, 2023

China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) has secured a non-exclusive worldwide license to develop and...

Company Deals

Vas Healthcare Raises RMB 100 Million in Angel Financing for Robot Development

Fineline Cube Mar 20, 2023

Vas Healthcare, a developer of vascular interventional surgery robots based in Beijing, has reportedly raised...

Company Drug

Hainan Poly Pharm’s Generic Gadovist Receives FDA Approval for MRI Use

Fineline Cube Mar 20, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received marketing...

Company Drug

Jacobio Pharma’s JAB-24114 Receives CDE Approval for Phase I/IIa Clinical Study

Fineline Cube Mar 20, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center...

Company Drug

Hengrui Pharmaceuticals’ Dexmedetomidine Nasal Spray Approved by NMPA

Fineline Cube Mar 20, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing...

Company Deals

Asiflyer Bio Raises Millions in Pre-Series A Funding for Botox and ZFP Technology

Fineline Cube Mar 20, 2023

Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi...

Company Drug

Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013

Fineline Cube Mar 20, 2023

Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...

Company Drug

Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor

Fineline Cube Mar 20, 2023

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...

Company Deals

Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities

Fineline Cube Mar 20, 2023

China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan...

Company Drug

Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval

Fineline Cube Mar 20, 2023

Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...

Company Medical Device

AffaMed Technologies’ EDOF Intraocular Lenses Receive FDA Approval in Taiwan

Fineline Cube Mar 20, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it...

Company Drug

Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine

Fineline Cube Mar 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy...

Company Drug

AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China

Fineline Cube Mar 17, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...

Company Deals

Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development

Fineline Cube Mar 17, 2023

Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel...

Company Drug

NMPA Accepts Market Filing for Guangdong Zhongsheng’s COVID-19 Drug RAY1216

Fineline Cube Mar 17, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that the market filing for...

Company Drug

Mabwell Bioscience’s 9MW3811 Gains NMPA Approval for Clinical Trials in China

Fineline Cube Mar 17, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Company Drug

Everest Medicines’ Xerava Receives NMPA Approval for Complicated Intra-Abdominal Infections

Fineline Cube Mar 17, 2023

China-based Everest Medicines Limited (HKG: 1952) has announced that it has received market approval from...

Company Deals

Terumo Blood and Cell Technologies Partners with EurekaBio to Establish Cell Therapy Lab

Fineline Cube Mar 17, 2023

US-based Terumo Blood and Cell Technologies has entered into a partnership with Shenzhen-headquartered EurekaBio Technology...

Policy / Regulatory

Beijing Initiates Volume-Based Procurement for Ophthalmology and Orthopedics Medical Consumables

Fineline Cube Mar 17, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification regarding the volume-based procurement (VBP)...

Posts pagination

1 … 547 548 549 … 664

Recent updates

  • Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma
  • Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC
  • Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration
  • Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention
  • Haisco Pharmaceutical’s Sishujing Seeks Postoperative Pain Indication, Expanding Peripheral Kappa Agonist Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma

Company Drug

Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC

Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Company Drug

Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.